This Taiwan-first, AI-driven peptide drug development platform, centered on CatiPep®, integrates multi-omics analysis with mechanism-guided design. Supported by intellectual property protection and validated in large-animal goat preclinical studies, it promotes cartilage regeneration and suppresses inflammation. The platform is designed for disease-modifying osteoarthritis (DMOAD) and holds strong potential for clinical translation and commercialization.

This technology establishes a peptide-centric, AI-integrated drug development platform that overcomes small-molecule–biased limitations by enabling prediction of sequence–structure–function, PK, and ADMET relationship. It incorporates peptide-specific features such as protease degradation and conformational dynamics, improving accuracy. Through GPCR-based modeling and a closed-loop AI–experiment framework, it advances CatiPep® as a disease-modifying OA candidate with translational potential.

This technology establishes an AI-driven peptide drug development platform centered on CatiPep®, addressing key industry challenges in osteoarthritis (OA), including the lack of disease-modifying therapies and low development efficiency. It is applicable to new drug development, clinical medicine, and veterinary markets, enhancing development efficiency, therapeutic efficacy, and scalability, while reducing costs and translational risks, demonstrating strong clinical and commercial potential.